ArticleDiscover oncology2025
Bone marrow mesenchymal stem cells-derived exosomes deliver microRNA-142-3p to disturb glioma progression by down-regulating GFI1.
Article in Discover oncology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
3 citing papers in PubMed.
- Cellular Allies Against Glioblastoma: Therapeutic Potential of Macrophages and Mesenchymal Stromal Cells.Pharmaceutics · 2026Review
- P4HB regulates tumor-associated macrophage polarization and chemotaxis by enhancing IL-6 cytokine secretion in glioblastoma.Annals of medicine and surgery (2012) · 2025Article
- LDMP-RENet: Reducing intra-class differences for metal surface defect few-shot semantic segmentation.PloS one · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
objectiveThe mechanism of glioma development has been extensively explored and comprehension of the exosomal microRNA-142-3p/growth factor independent-1 (miR-142-3p/GFI1) axis in glioma is still at an initial stage. Therein, the conducted work goes toward ascertaining the role of the bone marrow mesenchymal stem cells-derived exosomes (BMSCs-Exos)/miR-142-3p/GFI1 axis in glioma development.
methodsCancer tissues from patients with glioma and normal brain tissues from those who underwent surgery for traumatic brain injury were collected. miR-142-3p and GFI1 expression in tissues and cells were measured. Exos derived from BMSCs carrying miR-142-3p were cocultured with glioma cells to observe the effects of exosomal miR-142-3p on glioma cell invasion, migration, and apoptosis. The targeting relationship of miR-142-3p and GFI1 was validated. A series of rescue assays were conducted to further investigate whether GFI1 is implicated in the exosomal miR-142-3p-mediated regulation of glioma cell invasion, migration, and apoptosis.
resultsmiR-142-3p was low-expressed in glioma tissues and cells, and the low expression had an association with unwanted prognosis. Exos-shuttled miR-142-3p suppressed the migration and invasion, while promoting apoptosis of glioma cells. Further investigation revealed that GFI1 was a direct target of miR-142-3p, and re-expression of GFI1 neutralized the inhibitory effects of exosomal miR-142-3p.
conclusionExosomal miR-142-3p suppressed glioma cell migration and invasion and stimulated apoptosis by targeting GFI1.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.